Russell Investments Group
CTMX icon

Russell Investments Group’s CytomX Therapeutics CTMX Stock Holding History

Russell Investments Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,576
Closed -$28.3K – 3864
2025
Q1 		$28.3K Buy
44,576
+10,522
+31% +$8.16K ﹤0.01% 3035
2024
Q4 		$35.1K Sell
34,054
-13,595
-29% -$14.6K ﹤0.01% 2899
2024
Q3 		$56.2K Buy
47,649
+4,835
+11% +$6.14K ﹤0.01% 2766
2024
Q2 		$52.2K Buy
42,814
+16
+0% +$32 ﹤0.01% 2755
2024
Q1 		$93.3K Buy
42,798
+1,073
+3% +$1.98K ﹤0.01% 2584
2023
Q4 		$64.7K Sell
41,725
-3,901
-9% -$5.13K ﹤0.01% 2611
2023
Q3 		$58.9K Sell
45,626
-8,079
-15% -$12.7K ﹤0.01% 2727
2023
Q2 		$92.4K Sell
53,705
-3,350
-6% -$5.56K ﹤0.01% 2619
2023
Q1 		$86.2K Sell
57,055
-1,192
-2% -$2.69K ﹤0.01% 2616
2022
Q4 		$93.2K Sell
58,247
-3,073
-5% -$4.55K ﹤0.01% 2682
2022
Q3 		$88K Sell
61,320
-174,150
-74% -$268K ﹤0.01% 2688
2022
Q2 		$429K Buy
235,470
+150,091
+176% +$287K ﹤0.01% 2318
2022
Q1 		$227K Sell
85,379
-45,672
-35% -$175K ﹤0.01% 2434
2021
Q4 		$567K Sell
131,051
-35,359
-21% -$207K ﹤0.01% 2398
2021
Q3 		$846K Sell
166,410
-2,053
-1% -$11K ﹤0.01% 2261
2021
Q2 		$1.06M Sell
168,463
-16,045
-9% -$125K ﹤0.01% 2281
2021
Q1 		$1.42M Sell
184,508
-43,734
-19% -$346K ﹤0.01% 2081
2020
Q4 		$1.5M Sell
228,242
-259,428
-53% -$1.85M ﹤0.01% 1910
2020
Q3 		$3.24M Buy
487,670
+384,490
+373% +$2.85M 0.01% 1394
2020
Q2 		$857K Buy
103,180
+9,202
+10% +$85.5K ﹤0.01% 2140
2020
Q1 		$718K Buy
93,978
+50,084
+114% +$349K ﹤0.01% 2006
2019
Q4 		$363K Buy
+43,894
New +$296K ﹤0.01% 2512
2018
Q4 		– Sell
-25,248
Closed -$467K – 2935
2018
Q3 		$467K Sell
25,248
-101,571
-80% -$2.31M ﹤0.01% 2418
2018
Q2 		$2.9M Sell
126,819
-64,382
-34% -$1.64M 0.01% 1559
2018
Q1 		$5.44M Buy
191,201
+83,448
+77% +$2.38M 0.01% 1324
2017
Q4 		$2.38M Buy
107,753
+92,305
+598% +$1.91M ﹤0.01% 1735
2017
Q3 		$281K Sell
15,448
-6,686
-30% -$104K ﹤0.01% 2603
2017
Q2 		$343K Buy
22,134
+292
+1% +$4.4K ﹤0.01% 2548
2017
Q1 		$377K Hold
21,842
– – ﹤0.01% 2530
2016
Q4 		$243K Buy
+21,842
New +$265K ﹤0.01% 2669

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Russell Investments Group's CTMX Position: Q2 2025 in Review

Russell Investments Group sold out of CytomX Therapeutics (CTMX) in Q2 2025, closing a stake of 44,576 shares — an estimated $28.3K sold.

Russell Investments Group first reported a position in CTMX in Q4 2016 and held it in 30 quarters. The position peaked at $5.44M in Q1 2018. 83 funds tracked by Wall St. Rank hold CTMX as of Q2 2025.

  • Russell Investments Group reported no remaining CytomX Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Russell Investments Group sold 44,576 CytomX Therapeutics shares in Q2 2025, an estimated $28.3K.
  • Russell Investments Group first reported a position in CytomX Therapeutics in Q4 2016 and held it in 30 quarters.
  • Russell Investments Group's CytomX Therapeutics position peaked at $5.44M in Q1 2018.
  • 83 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2025.

Based on Russell Investments Group's 13F filing for Q2 2025, filed 13 Aug 2025.